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摘要 
研究背景:台灣地區不論女性或男性肺癌皆高居癌症死亡率之
首位，而肺癌的發生與長期暴露於環境中的致癌物質有關，尤其是 
香菸中的成份 nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1- 
butanone ，簡 稱 NNK ， 被認為是造成肺癌主要的致癌物類型之一 。 NNK
除了會導致 DNA 的損害 (DNA  damage) 外 ， 近來研究也發現 NNK 容
易造成癌症形成過程中外顯基因變異 (epigenetic  alteration)，使抑癌
基因的啟動子上被過度甲基化。而造成啟動子 CpG 位置上過度甲基
化的 DNA 甲基轉移酵素 (DNA methyltransferase, DNMT) 
DNMT1、DNMT 3a 及 DNMT 3b，目前也已發現在癌細胞中有過度
表現的情形。 
研究目的:  本實驗室先前針對肺癌做了許多與抑癌基因 CpG 過
度甲基化相關的研究，並發現 DNMTs 的過度表達與抽煙的肺癌病
人有顯著的相關性，然而造成此現象的詳細機制仍不清楚。因此本
篇研究目的為以細胞、臨床及動物模式探討香菸致癌物 NNK 是透過
何種機制而誘導 DNMTs 表達，進而導致許多抑癌基因啟動子 CpG
位置過度甲基化的現象。 
研究方法及結果:  首先在細胞模式由西方轉漬法 (Western  Blot) 
發現處理香菸中的尼古丁 (nicotine)  6 小時後，會促使 DNMT1 蛋白
表現增加；而由 nicotine 所衍生出來的致癌物 NNK 則是在隨其處理
濃度及時間增加 ， DNMT1 蛋白表現也隨之增加 ， 尤其在 10 μM NNK
處理 2 小時即有很明顯誘導效果；同時藉由外送 DNMT1 載體表現
分析實驗也得知 NNK 會誘導外生性 DNMT1 蛋白表現增加 ； 然而透
過反轉錄聚合酵素鏈反應 (RT-PCR) 得知 NNK 處理 2 小時並不會  2
影響 DNMT1 mRNA  的表達改變。進一步，處理可以抑制新蛋白質
生成的轉譯抑制劑 Cycloheximide 得知 DNMT1 蛋白的半衰期大約 6
小時，但是同時受到 NNK 刺激後，DNMT1 蛋白的半衰期增長為 24
小時。本研究結果亦顯示 nicotine 及 NNK 在 2 小時內與 p-NFκB、
p-AKT、p-ERK1/2 及 p-p38 的訊息蛋白活化有關；更進一步由處理
AKT抑制劑 (LY294002)  及AKT knock down實驗得知NNK會透過
AKT 訊息路徑影響 DNMT1 蛋白表現的增加。由免疫沈澱法 
(Immunoprecipitation)、蛋白質降解抑制劑 (MG132) 處理等實驗證
明NNK透過AKT訊息路徑影響泛素 (ubiquitin) 調節的蛋白質體降
解系統而增加 DNMT1 蛋白的穩定性；此外，更進一步利用 GSK3β
抑制劑及分別外送 GSK3β、βTrCP 載體表現來驗證 GSK3β/βTrCP
路徑會促使 DNMT1 蛋白降解，但 NNK 則會活化 AKT 而影響
GSK3β/βTrCP 路徑使 DNMT1 不易被降解。由免疫沈澱法也首度證
實 DNMT1 蛋白會與 GSK3β 及 βTrCP 蛋白結合，由此可知
GSK3β/βTrCP 蛋白降解路徑的確會影響 DNMT1 蛋白調控。接下來
我們以染色質沈澱的聚合酶鏈鎖反應(chromatin 
immunoprecipitation-polymerase chain reaction assay) 及聚合酵素鏈
反應為基礎的甲基化分析 (methylation-specific PCR) 方法發現
NNK 所誘導的 DNMTs 表現會結合至抑癌基因啟動子區域，進而造
成抑癌基因啟動子有過度甲基化的情形。 
在動物模式實驗中，以免疫組織染色分析 NNK 處理及未處理
的老鼠肺組織切片，發現 NNK 處理後所產生肺腫瘤組織的
DNMT1、DNMT3B、p-AKT 與不活化態的 p-GSK3β(ser9)蛋白表現
比較高，而βTrCP 蛋白則有下降表現的情形。 
在臨床研究方面 ， 我們以免疫組織染色分析(Immunohistochemistry)  3
偵測 109 位臨床肺癌病人 DNA 甲基轉移酵素表現量，發現曾經吸
煙但後來有戒煙病人的 DNMT1 蛋白過度表現情形 (31.1%) 比持續
吸煙病人的 DNMT1 蛋白過度表現情形 (69.4%) 明顯來的低 ( P 值
=0.001)。 
結論:  由以上細胞、臨床及動物模式實驗結果顯示，香菸中致
癌物 NNK 的確會誘導 DNMTs 蛋白表現的增加；進一步由細胞實驗
結果也知 NNK 會透過 AKT 訊息路徑削弱 GSK3β/βTrCP 調控
DNMT1 蛋白降解作用，進而使 DNMT1 蛋白質穩定性增加；而這些
NNK 所誘導的 DNMTs 蛋白也會結合到抑癌基因的啟動子位置上，
進而導致抑癌基因啟動子產生過度甲基化的情形，因此成為導致肺
癌發生的原因之一。   4
ABSTRACT 
Background:  Most lung cancer cases are caused by 
cigarette-specific carcinogens, such as nitrosamine 4-(methylnitrosamino) 
-1-(3-pyridyl)-1-butanone (NNK). Previous studies have shown that NNK 
induces promoter hypermethylation of several tumor suppressor genes 
(TSGs) in mouse models. However, the mechanism involved in the 
promoter hypermethylation induced by NNK remains unclear. DNA 
methylation is carried out by DNA methyltransferases (DNMTs), which 
have been shown to be overexpressed in human cancers including lung 
cancer. 
Purpose:  Our previous study showed that smoking lung cancer 
patients have a significant high level of DNMTs expression. Therefore, 
the present study aims to investigate what mechanisms involved in 
DNMTs overexpression induced by a cigarette carcinogen, NNK, in 
lung cancer by cell, animal, and clinical models. 
Results: Western blot assays indicated that DNMT1 and DNMT3b 
increased after treated with pro-carcinogen, nicotine for 6 h in IMR90, 
A549, and H1299 lung cells. In addition, nicotine-derived carcinogen, 
NNK treatment for 2 h increased endogenous and exogenous DNMT1 
protein levels but not mRNA expression level in A549 and H1299 lung 
cells, suggesting that NNK-induced DNMT expression occurs at the 
post-translational level. Treatment with translation inhibitor 
cycloheximide with or without combining treatment of NNK confirmed 
that NNK indeed prolonged DNMT1 protein half-life. In addition, NNK   5
activated phosphorylation of AKT, NFκB, ERK1/2, and p38 pathways in 
IMR90 and A549 cells. Note that AKT pathway was significantly 
stimulated by NNK between 15 and 120 min in these cells. To evaluate 
the involvement of AKT signaling pathway in DNMT1 protein 
accumulation after NNK treatment, cells were treated with AKT 
inhibitor, LY294002, or AKT siRNA knock down oligos. The results 
indicated that NNK increased DNMT1 protein level can be abolished by 
both AKT inhibition treatments. In addition, immunoprecipitation assay 
suggested that NNK increased DNMT1 protein stability through AKT 
signaling pathway and was associated with ubiquitination protein 
degradation system. This conclusion was validated by combining 
treatment of AKT inhibitor and proteasome inhibitor MG132 in A549 
and IMR90, which abolished the DNMT1 degradation induced by AKT 
inhibitor.  
Since AKT downstream GSK3β/βTrCP ubiqutin-proteasome 
pathway has been implicated in degradation of many proteins. We 
investigated whether GSK3β/βTrCP ubiqutin-proteasome pathway was 
involved in NNK-induced DNMT1 protein stability. We treated the cells 
with GSK3β inhibitor, SB415286, in the presence of NNK. In addition, 
cells overexpressing different levels of GSK3β or βTrCP construct were 
analyzed for DNMT1 protein level. The data indicated that NNK 
induced DNMT1 protein stability resulted from attenuation of 
GSK3β/βTrCP-mediated DNMT1 protein degradation system. In 
addition, we found that DNMT1 protein interacted with GSK3β and βTrCP by 
immunoprecipitation assay.  Furthermore, chromatin-immunoprecipitation   6
PCR and methylation-specific PCR assays showed that increased 
DNMT1 indeed bound to methylated TSG promoters after treated with 
NNK. 
In animal model data, immunohistochemical staining assay showed 
that NNK increased protein expression level of DNMT1, DNMT3B, 
p-AKT, and inactive form of p-GSK3β (ser9) in mice adenoma lung 
tissue treated with NNK. However, protein expression level of βTrCP 
was reduced in NNK-treated mice adenoma lung tissue. 
In clinical data, immunohistochemical staining for the DNMT1 
protein expression was performed on 109 NSCLC tumor samples with 
smoking status data available. The results indicated that DNMT1 protein 
expression level was significantly higher in smoking patients compared 
to non-smoking patients including ex-smokers and never smokers 
(P<0.001). Interestingly, the DNMT1 protein of ex-smoke patients were 
expressed at a significantly lower level in tumor nuclear compared to 
that found in still-smoking patients (P=0.001). 
Conclusion:  These data suggest that deregulation of DNMTs is 
associated with the NNK-induced DNMT stability by 
AKT/GSK3β/βTrCP pathway and results in epigenetic alteration of 
target TSGs and ultimately leads to lung cancer.   7
INTRODUCTION 
Ⅰ. The pathogenesis of lung cancer 
Lung cancer is one of the most common cancers in the world and is 
the leading cause of cancer-related deaths in industrial countries (Jemal 
et al., 2004). Lung cancer incidence has risen dramatically for both men 
and women in Taiwan. In 2006, an estimated 211.0 and 120.7 patients 
among 100,000 Taiwanese male and female individuals, respectively, 
were killed by lung cancer (Department of Health, Taiwan, 2007). 
According to the World Health Organization (WHO) conference 
convened in Geneva in 1982, the histological types of lung cancer can 
be divided into small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC), which further classified into squamous cell carcinoma 
(SCC), adenocarcinoma (AD), and large cell carcinoma (LC). 
The tumor, node, and metastasis (TNM) staging system for NSCLC, 
developed by the American Joint Committee on Cancer, has provided 
specificity for identifying patient groups with similar prognoses and 
treatment options. The present classifications are: local: stages IA, IB, 
and IIA; locally advanced: stages IIB, IIIA, and IIIB; advanced: stages 
IIIB and IV. For stage I: cancer cells still stay in lung; for stage II and III: 
cancer cells have transferred to lymph node, and the last stage, cancer 
cells start metastasis (Mountain, 1997; Spira and Ettinger, 2004; Collins 
et al., 2007). The prognosis of lung cancer is very poor with almost 70% 
of the patients dying from the disease within two years of diagnosis 
(Bains, 1991; Spira and Ettinger, 2004). Therefore, improvements in   8
early detection, couple with identification of what mechanism that 
involve in lung cancer, could help reduce the death rate for it. 
Molecular abnormalities lead to lung cancer pathogenesis including 
oncogenes activation and tumor suppressor genes (TSGs) inactivation 
(Sekido et al., 1998). Oncogenes can be activated by mutation, gene 
amplification, and chromosomal translocation (Salomon-Nguyen et al., 
2000; Thomas et al., 2007; Lockwood et al., 2008).  Promoter 
hypermethylation is an alternative mechanism to inactivate TSGs other 
than gene deletion and mutation, and is a major epigenetic modification 
in mammalian genome that is not accompanied by changes in DNA 
sequence (Nephew and Huang, 2003). 
Ⅱ. Smoking and lung cancer 
About 87% of lung cancer cases are caused by cigarette smoking. 
SCLC and SCC lung cancer patients are mostly smokers (Hecht, 2002). 
Smoking has been associated with decreased survival following diagnosis 
with a variety of cancers, including lung, kidney, stomach, liver, colon, 
renal body, cervix, and myeloid leukaemia. Thus, patients who have a 
history of heavy smoking or ongoing smoking habit are at risk of death 
from a spectrum of smoking-associated diseases (Tammemagi et al., 
2004). 
(a) The species of cigarette-specific carcinogen 
Environment contains a variety of carcinogens including chemical, 
physical, or other factors that cause cancer or increase the incidence of   9
cancer. There are 4000 identified chemicals in cigarette smoke, more than 
60 are established carcinogens (Hoffmann et al., 2001). The strongest 
types of carcinogens are polycyclic aromatic hydrocarbons (PAHs), 
aromatic amines, N-nitrosamines, and other alkylating agents. In relation 
to human lung cancer, the most important carcinogens are PAHs such as 
benzo(a)pyrene and the tobacco specific nitrosamine family, including 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 
N’-nitrosonornicotine (NNN), 4-(methylnitrosamino)-4-(3-pyridyl)- 
butanal (NNA), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol 
(NNAL),  N’-nitrosoanabasine (NAB), N’-nitrosoanatabin (NAT), 
4-(methylnitrosamino)-4-(3-pyridyl)-butanol  (iso-NNAL), and 
4-(methylnitrosamino)-4-(3-pyridyl)-butanoic acid  (iso-NNAC)  (Hecht, 
1999, 2002)  (Fig.  1).  Therefore, NNK is considered to be a major 
contributor to lung carcinogenesis in smokers. 
(b) The metabolism of Nitrosamine 
4-(methylnitrosamino)-1-(3-pyridyl) -1-butanone (NNK) 
Nicotine in cigarette smoke can be converted into carcinogen such as 
NNK which is metabolically activated by cytochrome P450. Some of the 
intermediates formed by the interaction of cytochrome P450 enzyme with 
carcinogens are reactive  to DNA to form DNA damage. These 
intermediates have electrophilic affinity center then lead to react with 
DNA, and result in the formation of covalently bound products known as 
DNA adducts. The major metabolic event of NNK is conversion of the 
carbonyl group in NNK to an alcohol with the formation of NNAL. This   10
product is also a potent pulmonary carcinogen. NNAL in turn is 
metabolized by glucuronidation of the alcohol and pyridine ring 
(NNAL-N-Gluc and NNAL-O-Gluc; collectively NNAL glucuronide, 
NNAL-Gluc). NNAL is conjugated to its presumed detoxified product, 
NNAL-Gluc, by UDP-glucuronosyltransferases (UGTs) and then is 
excreted in the urine (Muscat et al., 2005) (Fig 2).   
Ⅲ. The epigenetic alteration of cancers involved in NNK 
A lot of studies demonstrate that NNK causes DNA damage, 
including single-strand DNA breaks, DNA adducts, alkylphosphotriester 
formation, and increased oxidative stress (Liu et al., 1990; Singer, 1996; 
Holmquist and Gao, 1997; Cloutier et al., 2001). In addition, many 
studies show that NNK correlates with epigenetic alteration of cancers 
(Pulling et al., 2001; Vuillemenot et al., 2006). DNA methylation and 
histone acetylation are two major epigenetic pathways, which cause 
tightly packed chromatin conformations and are associated with the 
suppressed state of transcription (Xiong et al., 2005). There are many 
clinical studies indicated that smoking is associated with promoter 
hypermethylation at multiple TSGs in lung and bladder cancers. These 
hypermethylated genes include p16
INK4A, FHIT, RAS association domain 
family 1A (RASSF1A), and secreted frizzled related proteins (Kim et al., 
2003; Kim et al., 2004; Marsit et al., 2006). In mice studies, cigarette 
smoking exposure induces hypermethylation of the death-associated 
protein kinase 1 (DAPK1), RARβ,  and  runt-related transcription 
factor-3 gene promoters (Pulling et al., 2004; Hutt et al., 2005;   11
Vuillemenot et al., 2006).  In rat studies, NNK promotes  p16
INK4A 
promoter hypermethylation and mutation of the β-catenin gene in liver 
tumor (Pulling et al., 2001). 
(a) Promoter hypermethylation of tumor suppressor genes 
The cancer cells undergo changes in 5’-methylcytosine distribution 
including global DNA hypomethylation and the region-specific 
hypermethylation of promoter CpG islands associated with TSGs have 
long been known (Laird, 2005). Aberrant promoter hypermethylation of 
CpG islands associated with TSGs leads to transcriptional silencing and 
results in tumorigenesis. DNA methylation is frequently not restricted to 
a single CpG island but affects multiple independent loci, reflective of a 
widespread deregulation of DNA methylation pattern in different types 
of tumors (Momparler, 2003; Belinsky, 2004). Silencing of TSGs 
mediated by DNA methylation is an important player in processes of 
tumorigenesis including hMLH1,  glutathione S-transferase 1, 
O
6-methylguanine-DNA methyltransferase (MGMT), and breast cancer 
1 (BRCA1) for DNA repair; p16
INK4a, p15
INK4b, and RB for cell cycle 
control;  RASSF1A for growth inhibition, E-cadherin ( CDH1), 
H-cadherin ( CDH13), and tissue inhibitor of metalloproteinase 3 
(TIMP3) for inhibition of metastasis; DAPK1 for induction of apoptosis 
(Robertson, 2001). 
(b) The structure and function of DNA methyltransferases 
DNA methylation is carried out by DNA methyltransferases 
(DNMTs). DNMTs methylate the cytosine residue of CpGs, and five   12
types have been identified (DNMT1, 2, 3a, 3b, and 3L). Their functional 
domain map is shown in Fig. 3. 
DNMT1 comprises a large N-terminal domain with regulatory 
function and a smaller C-terminal catalytic domain (Hermann et al., 
2004).  The regulatory domain harbors different motifs, like a 
charge-rich domain that interacts with the DMAP1 transcriptional 
repressor, a proliferating cell nuclear antigen (PCNA) interacting 
domain, a replication foci targeting region, a nuclear localization signal 
region, a bromo-adjacent homology, a cysteine-rich zinc binding CXXC 
domain, and contains different start codons (Hermann et al., 2004). The 
bromo-adjacent homology is found in a number of chromatin-associated 
proteins and acts as a protein-protein interaction module specialized in 
gene silencing, and might therefore play an important role by linking 
DNA methylation, replication, and transcriptional silencing (Callebaut et 
al., 1999). The DNMT1 polybromo domain is supposed to play a role in 
the transport of DNMT1 to the replication foci (Liu et al., 1998). The 
cysteine-rich zinc binding CXXC requires zinc for efficient DNA 
binding activity and is conserved in DNMT1 and methyl binding 
domain protein 1  (MBD1)  (Lee et al., 2001). In summary, the 
N-terminal part of DNMT1 seems to be involved in the intracellular 
delivery and regulation of catalytic activity of DNMT1. Enzyme activity 
is only observed in the presence of a substantial part of the N-terminal 
region (Zimmermann et al., 1997). Most likely through intramolecular 
interaction of these domains, a conformational change of the catalytic 
domain of DNMT1 into an active conformation is induced (Hermann et   13
al., 2004). DNMT1 is referred to as a “maintenance” methyltransferase 
and is the primary enzyme responsible for copying methylation patterns 
after DNA replication because it localizes to replication foci and 
interacts with PCNA (Chuang et al., 1997). 
DNMT2 was identified in 1998, which lacks the large N-terminal 
regulatory domain (Hermann et al., 2004). A weak but reproducible 
methyltransferase activity to DNA is recently demonstrated for the 
recombinant DNMT2 protein (Hermann et al., 2003). Recent evidence 
shows that DNMT2 has a novel tRNAP
ASP methyltransferase activity 
(Jeltsch et al., 2006). However, the biological role of the methylation of 
tRNA
Asp remains unclear. 
The DNMT3 family consists of DNMT3a and DNMT3b, which are 
highly related to each other but are encoded by separate genes. The 
DNMT3a and DNMT3b
  proteins are very similar in structural 
organizations. Their
  N-terminal regulatory domains contain two 
conserved regions, a PWWP domain and a cysteine-rich
 domain that 
shares homology with a region in ATRX transcriptional regulation 
protein (Siedlecki and Zielenkiewicz, 2006). DNMT3a and DNMT3b 
are responsible for the wave of de novo methylation during early 
embryogenesis, which establishes the somatic methylation pattern 
(Okano et al., 1998; Okano et al., 1999; Oka et al., 2005). 
The third member of the DNMT3 family is DNMT3L, showing 
clear homology to the DNMT3a and 3b enzymes (Hermann et al., 2004). 
Its N-terminal part comprises just the PHD domain; the C-terminal part 
extends to the conserved motif VIII lacking of many other motifs   14
important for catalysis of the methyltransferase reaction making it 
unlikely to be a functional methyltransferase (Robertson, 2001; 
Hermann et al., 2004). Although enzymatically inactive, DNMT3L is 
shown to act as a general stimulatory factor for de novo methylation by 
DNMT3a (Chedin et al., 2002). The C-terminus of DNMT3L is required 
for interaction with DNMT3a and DNMT3b to assist their function 
(Chen et al., 2005). 
(c) The expression level of DNMTs in cancer 
There are reports of up-regulation of  DNMTs mRNA or protein 
expression levels in human tumors such as hepatoma, prostate, 
colorectal, gastric, transitional cell carcinoma, breast, and lung tumors 
(Table 1). Our laboratory has recently shown a comprehensive 
molecular and clinical association study for all three major DNMTs in 
the same serious of lung cancer cohort. The data indicate that mRNA 
and protein of DNMT1, DNMT3a, and DNMT3b are overexpressed in 
lung cancer patients (Lin et al., 2007).
 
(d) The unsolved question of mechanism involved in promoter 
hypermethylation in relation to cigarette carcinogenesis 
We previously found that promoter hypermethylation plays an 
important role in the inactivation of certain TSGs including p16
INK4a, 
p14
ARF, hMLH1, hMSH2, RARβ, and FHIT in NSCLC patients (Chen et 
al., 2001; Wang et al., 2003; Hsu et al., 2004; Tzao et al., 2004b, a; 
Wang et al., 2006). In addition, we recently show  that alteration of 
DNMTs expression correlates with multiple TSG promoter   15
hypermethylation especially in smoking lung cancer patients (Lin et al., 
2007). Furthermore, Hammons et al. (1999) show that DNMT mRNA is 
overexpressed in liver tumor of smoking patient. Liu et al. (2007) find 
that cigarette smoke extract induces DNMT1 protein levels in A549 
lung cancer cell.  However, the mechanism underlying the 
hypermethylation of CpG islands in the TSGs relevant to tobacco and/or 
environmental carcinogenesis has not been elucidated. In addition, the 
role of DNMT in the tobacco carcinogen-induced promoter 
hypermethylation of TSGs remains unclear. Note that NNK alters many 
signal transduction pathways of treated cells or animals. Therefore, we 
propose that the cigarette carcinogen could induce overexpression of 
DNMTs through some signaling pathways and lead to hypermethylation 
at multiple TSG promoters that we observed. 
Ⅳ. Previous studies on signaling pathways involved in 
NNK and DNMTs 
Study of NNK-induced AD in hamsters demonstrates the 
simultaneous overexpression of β2-adrenergic receptor pathway, 
including PKA, cAMP, and phosphorylated CREB as well as of an 
EGFR pathway, including overexpression of EGFR-specific 
phosphorylated tyrosine kinase, Raf-1, ERK1/2 and their 
phosphorylated forms (Schuller and Cekanova, 2005; Cekanova et al., 
2007). In addition, cigarette-specific carcinogen NNK treatments results 
in  β2-adrenergic receptor transactivation of the EGFR and 
phosphorylation of ERK1/2 in immortalized human pancreatic duct 
epithelial cells (Askari et al., 2005).  Moreover, nicotine and NNK   16
activate the AKT and NFκB pathways and increase lung cancer cell 
proliferation and survival (Tsurutani et al., 2005; Carlisle et al., 2007). 
Nicotine also leads to development of human lung cancer through 
multi-site phosphorylation of Bad (Jin et al., 2004a). In addition, NNK 
activates ERK1/2 and CREB/ATF-1 via β1-adrenergic receptor pathway 
and EGFR signaling in human lung AD and small airway epithelial cells 
(Laag et al., 2006). NNK regulates cell survival and proliferation 
through functional cooperation of Bcl2 and c-Myc phosphorylation (Jin 
et al., 2004b). Note that active AKT is detected in airway epithelial cells 
and lung tumors from NNK-treated A/J mice, and in human lung 
cancers derived from smokers (West et al., 2003). 
As previously discussed in paragraph (d) of section III, NNK 
induces DNMTs overexpression. However, it is poorly understood what 
signaling involves in NNK-induced DNMTs alteration and thus leading 
to hypermethylation at multiple TSG promoters. Therefore, the current 
study aims to investigate what signal pathways are involved and how 
DNMTs are regulated by NNK. 
Ⅴ. Previous studies on post-translational modifications   
of DNMTs 
Many studies have pointed that increases in DNMT1 mRNA, 
DNMT1 protein, and DNMT activity accompany carcinogenesis. Some 
have considered that an increase in DNMT1 mRNA in human tumor 
samples (el-Deiry et al., 1991; Issa et al., 1993; Belinsky et al., 1996), 
but others have found stability of DNMT1 protein in tumor cell which 
compared to normal cell (Agoston et al., 2005). DNMT1 protein   17
stability is abnormally elevated because of defective degradation which 
relates with a destruction domain mapped to the N-terminal 120 amino 
acids of DNMT1 (Agoston et al., 2007). Recent research has suggested 
that increase of  DNMT1 protein stability is due to inhibition of its 
ubiquitin proteasome-mediated degradation through activation of 
PI3K/AKT. It has also been pointed that AKT stabilizes DNMT1 protein 
by correlation with glycogen synthase kinase 3β (GSK3β) (Sun et al., 
2007). 
GSK3 is originally identified as a Ser-/Thr-protein kinase and it has 
two isoforms in human cells, including GSK3α and GSK3β. There are 
facilitative autophosphorylations of GSK3α  (Tyr-279)  and GSK3β 
(Tyr-216) required for GSK3 activity (Hughes et al., 1993; Cole et al., 
2004). Oppositely, there are regulatory phosphorylations of GSK3α 
(Ser-21) and GSK3β (Ser-9) which inhibit their kinase activities through 
PKB/AKT (Frame and Cohen, 2001; Cohen and Goedert, 2004; Markou 
et al., 2008). Recent studies have identified that GSK3 phosphorylates a 
number of proteins including p21 (Rossig et al., 2002), cyclin D (Diehl 
et al., 1998), c-Myc (Sears et al., 2000), β-catenin (Aberle et al., 1997), 
and C/EBPα  (Shim and Smart, 2003)  and in doing so targets these 
molecules for proteasomal degradation. Therefore, elucidation whether 
GSK3β is involved in NNK-induced DNMT protein accumulation is 
important.   18
PURPOSE 
NNK induces TSGs promoter hypermethylation are frequently 
found in human lung, liver, and bladder cancers and their derived cell 
lines. Our previous study published in 2007 also shows that inactivation 
of many TSGs by promoter hypermethylation in human lung cancer. 
Interestingly, smoking lung cancer patients have a significant high level 
of DNMTs overexpression. Some research indicate that half-life of 
DNMT1 protein is longer in tumor cell than that in normal cell and may 
be mediated by signaling pathways such as AKT. However, the clear 
mechanism of NNK-induced DNMTs accumulation has not been 
elucidated. Therefore, the present study is designed to investigate what 
mechanism could be involved in NNK-induced DNMTs accumulation, 
which results in 5’CpG hypermethylation of multiple TSGs  in lung 
cancer. The analyses were conducted in three parts including  cell, 
clinical, and animal models. 
In cell model: 
I.  Examine DNMTs expression alteration induced by NNK. 
II.  Examine whether NNK involves in control of DNMTs protein 
half-life. 
III. Examine what signaling pathways are involved in NNK-induced 
DNMT accumulation. 
IV. Examine whether deregulation of protein degradation signal 
proteins causes DNMTs expression alteration by NNK.   19
V.  Examine whether the NNK can induce alteration of DNMTs and 
then lead to hypermethylation on TSGs promoters. 
In animal model: 
--   Determine the alteration of DNMT1, DNMT3b, p-AKT, p-GSK3β, 
and βTrCP protein level in normal lung tissue of NNK-untreated 
mice and pre-cancer pulmonary lesions of NNK-treated mice. 
In clinical model: 
--   Identify whether DNMT1 expression level correlated with different 
smoking status of lung cancer patients. 
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MATERIALS 
Ⅰ. Carcinogens and chemical compounds 
The cigarette-specific carcinogen Nicotine (Sigma-Aldrich, St. 
Louis, USA) and NNK (Toronto Research Chemicals, North York, 
Canada) were used for cell model study and NNK was also used for 
animal model study. Chemical compounds for treatment of lung cells 
including cycloheximide (translational inhibitor), MG132 (proteosome 
inhibitor), and SB415286 (specific GSK3β inhibitor) were purchased 
from Sigma Chemical Company (St. Louis, MO, USA). LY294002 
(AKT inhibitor) was obtained from Calbiochem (San Diego, CA, USA). 
Ⅱ. Antibodies 
The antibodies used and the reaction conditions in the present study 
are shown in Table 2. These antibodies included DNMT1, DNMT3b, 
AKT, phosph-AKT, NFκB, phosph-NFκB, GSK3β, phosph-GSK3β 
(Ser9),  βTrCP, Erk1/2, phoph-Erk1/2, Ubiquitin, phosph-p38, p53, 
β-actin, and His-Tag. 
Ⅲ. Lung cell lines 
There were three lung cell lines used in the current study. One of 
them was normal cell line and the others were cancer cell lines. Their 
cell name, culture medium, and cell characteristics are listed in Table 3. 
These lung cell lines cultured in the 37
oC, 5% CO2 incubator, and 
culture medium (GIBCO, Grand Island, NY, USA) contains 10% fetal 
bovine serum (BIOCHROM AG, Leonorenstr, Berlin, Germany) and 1%   21
antibiotic (penicillin-streptomycin; GIBCO). 
Ⅳ. cDNA constructs 
The pOTB7-GSK3β was purchased from Open Biosystems 
(Huntsville, AL, USA). It was digested with EcoRI and XhoI, and then 
subcloned into EcoRI and  XhoI-digested pCMV-SPORT6 to generate 
pCMV-SPORT6-GSK3β. The other constructs included 
pCMV-SPORT6-βTrCP purchased from Open Biosystems and 
pcDNA3/V5/TOPO/His-full length DNMT1 obtained kindly from Dr. 
Li-Jung Juan at the Genomics Research Center, Academia Sinica. The 
plasmids used in the present study are shown in Table 4. 
Ⅴ. Animal studied 
The A/J mice were treated intraperitoneally (i.p.) with NNK at 2 
mg/0.1 ml saline/mouse, and i.p. with saline as a control-treated mice. 
The NNK-treated mice developed lung adenoma in 20 weeks. The 
animals were sacrificed by cervical dislocation. Normal lung and 
adenoma lung tissue samples were resected, fixed with formalin and 
embedded in paraffin for histologic examination, stained with 
hematoxylin and eosin for microscopic evaluation, and examined by a 
pathologist. These mouse tissues were kindly provided by Dr. Pinpin Lin 
at National Health Research Institutes. 
Ⅵ. Study population 
Surgically resected tumor samples from 109 patients diagnosed with 
primary NSCLC admitted to Veterans General Hospital, Taichung and   22
Taipei, were collected between 1993 and 2003. Information on the 
smoking history of the patients was obtained from hospital records. The 
smoking history was further divided into three groups, i.e., group I: 
smoking patients, group II: ex-smoker patients, and group III: never 
smoking patients. 
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METHODS 
In cell model 
Ⅰ. DNMTs expression assay 
(a) Nicotine and NNK treatment 
Lung cells were plated in 10cm culture dishes and incubated at 37
oC 
in a 5% CO2 atmosphere. The following day cells were treated with 100 
μM Nicotine for 0 h, 2 h, 4 h, 6 h, or 12 h at 37
oC, whereas NNK was 
treated at concentrations of 0 μM, 0.01 μM, 0.1 μM, or 10 μM for 2 h at 
37
oC. For time-course study, cells were treated with 10 μM NNK for 0 h, 
30 min, 2 h, or 4 h at 37
oC. 
(b) Full-length DNMT1 plasmid transfection assay 
We used pcDNA3/V5/TOPO/His-full length DNMT1 construct to 
investigate whether exogenous DNMT1 expression would be induced 
by NNK. Transfections were carried out with ExGen 500 (MBI 
Fermentas, Flamborough, Ontario, Canada) at a ratio of 3.3 μl of ExGen 
500 per 1 μg of DNA according to the manufacturer’s protocol. 
Transfected cells were then treated with 10 μM NNK for 2 h at 24 h 
post-transfection and prepared for Western blotting analysis. 
(c) Protein extraction and Western blotting analysis 
Cells were lysed on ice using the RIPA buffer (0.05 M Tris-HCl, pH 
7.4, 0.15 M sodium chloride (NaCl), 0.25% deoxycholic acid, 1% 
Nonidin P-40 (NP-40), 1mM ethylenednitrilotetraacetic acid (EDTA), 
0.5 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride, 5   24
µg/ml leupeptin, 10 µg/ml aprotinin). Lysates were then centrifuged at 
13,000 rpm. at 4°C for 15 min. Protein extracts were solubilized in 
sodium dodecyl sulfate (SDS) gel loading buffer (60 mM Tris base, 2% 
SDS, 10% glycerol, and 5% β-mercaptoethanol). Samples containing 
equal amounts of protein (50 µg) were separated on a 6 % sodium 
dodecyl sulfate-sodium dodecyl sulfate (SDS-PAGE) and electroblotted 
onto Immobilon-P membranes (Millipore Co., Bedford, MA, USA) in a 
transfer buffer. Immunoblotting was performed using antibodies against 
DNMT1 (1:10000), DNMT3a and DNMT3b (1:500), and β-actin 
(1:5000) as an internal control to confirm that the proteins were loaded 
equally. Each Western analysis was repeated three times. Quantification 
was performed using MultiGuauge soft system to obtain the mean and 
standard deviation values. 
(d) RNA extraction and reverse-transcriptase polymerase chain 
reaction (RT-PCR) assay 
The primers used and their PCR conditions in the present study are 
shown in Table 5. Expression levels of the DNMT1 gene was detected 
by a RT-PCR assay using the β-actin gene as an internal control. To 
quantify the relative levels of mRNA expression in the RT-PCR assay, 
the value of the internal standard (β-actin) in each reaction was used as 
the baseline gene expression of that sample and the relative value was 
calculated for the DNMT1 gene for lung cancer cells. The number of 
cycles, the amount of primers, and the cDNA used were determined to 
provide quantitative amplification during multiplex RT-PCR.   25
Ⅱ. DNMTs protein half-life assay 
To examine DNMT1 protein half-life in lung cells, cells were plated 
in 10 cm culture dishes and incubated at 37
oC in a 5% CO2 atmosphere 
on the day before analysis. Cells were treated with 10µg/ml 
cycloheximide for 0 h, 3 h, or 6 h. In addition, cells were treated with 10 
µg/ml cycloheximide for 6 h then combined with 10 µM NNK for 6 h, 
12 h, 24 h, or 48 h to confirm whether NNK could increase DNMT1 
protein half-life. Protein extraction and Western blotting analysis 
conditions were as described in paragraph (c) of section I. Each Western 
analysis was repeated three times and quantified as also described in 
section I (c). 
Ⅲ. Signaling proteins affected by Nicotine and NNK 
To discover what signaling pathways were affected by nicotine and 
NNK, cells were cultured and treated with 100 μM nicotine or 10 μM 
NNK for 2 h. Subsequently, proteins were extracted and immunoblotted 
using antibodies against Erk1/2 (1:1000), phoph-Erk1/2 (1:1000), AKT 
(1:1000), phosph-AKT (1:1000), NFκB (1:1000), phosph-NFκB 
(1:1000), phosph-p38 (1:2000), and β-actin (1:5000). Each Western 
analysis was repeated three times and quantified as described in section 
I (c). 
Ⅳ. Mechanism of NNK-induced DNMT1 protein stabilization 
(a) AKT knock down by RNA interference (RNAi) 
To examine whether AKT signaling was involved in NNK-induced 
increase of DNMT levels, RNAi depletion of AKT was performed in   26
cells treated with NNK. The RNA duplexes for knocking down of AKT 
were 5’-AUUCUUGAGGAGGAAGUAGCGUGGC-3’ and 
5’-GCCACGCUACUUCCUCCUCAAGAAU-3’, which were obtained 
from Invitrogen (Carlsbad, CA, USA), and transfection was performed 
with Lipofectamine LXT (Invitrogen) according to the manufacturer’s 
protocols. At 48 h post-transfection, immunoblotting for protein levels 
was performed with the following antibodies: AKT (1:1000), 
phosph-AKT (1:1000), DNMT1 (1:10000), and β-actin (1:5000). Each 
Western analysis was repeated three times and quantified as described in 
section I (c). 
(b) Immunoprecipitation and Western blotting (IP-Western) 
To investigate whether inhibition of ubiqutin-mediated protein 
degradation was involved in NNK-induced AKT activation and DNMT 
protein accumulation, cells were treated with 10 μM NNK or 20 μM 
LY294002, an AKT inhibitor. For immunoprecipitation, 1mg cell protein 
lysates were incubated with 4 μg of the appropriate antibody, including 
Ubiquitin (Chemicon), DNMT1 (Asia Hepato Gene Co), or Mouse-IgG 
(Upstate), and added 10 μl affinity ligand then added 1× wash buffer to 
final 500 μl  using the kit from Catch and Release Reversible 
Immuonprecipitation System (Uptate, Temecula, CA, USA). After 
incubation at 4
oC overnight, immune complexes were washed 3 times 
with 1× immonoprecepitation buffer [50 mM Tris-HCl, pH 7.5, 150 mM 
sodium chloride (NaCl), 20 mM α-glycerol-phosphate, 1% Nonidin 
P-40 (NP-40), 5 mM EDTA]. Proteins were eluted by boiling in 4× 
sample buffer, separated by 6% SDS-PAGE, then blotted with either   27
DNMT1 or Ubiquitin. 
(c) Proteosome inhibitor treatment 
Cells treated with 10 μM NNK, 20 μM LY294002, individually or 
together. In addition, cells were treated with  10  μM NNK, 20 μM 
LY294002, and 20 μM MG132 (a proteosome inhibitor) to confirm that 
AKT could involve in inhibition of DNMT1 protein degradation. 
Subsequently, extracted proteins were immunoblotted using antibodies 
against DNMT1 (1:10000), phosph-AKT (1:1000), and β-actin (1:5000). 
Each Western analysis was repeated three times and quantified as 
described in section I (c). 
Ⅴ. AKT downstream signaling proteins GSK3β and βTrCP mediate 
DNMT1 protein degradation 
(a) Plasmid transfection assay 
To examine whether GSK3β and βTrCP could regulate  DNMT1 
protein levels,  we used constructs pCMV-SPORT6-GSK3β and 
pCMV-SPORT6-βTrCP to perform  transfection assay. At 24 h 
post-transfection, extracted proteins were immunoblotted using 
antibodies against DNMT1 (1:10000), GSK3β (1:5000), phosph 
(Ser9)-GSK3β (1:500), βTrCP (1:500), and β-actin (1:5000). Each 
Western analysis was repeated three times and quantified as described in 
section I (c). 
(b) GSK3β inhibitor treatment 
Cells were treated with 25 μM SB415286 (a GSK3β inhibitor) and 
preceded to Western blotting analysis. The method was as described in   28
paragraph (a) of section V. Each Western analysis was repeated three 
times and quantified as described in section I (c). 
Ⅵ. Protein-protein interaction among DNMT1, GSK3β, and βTrCP 
-- Immunoprecipitation and Western blotting analysis 
Cells treated with 10 μM NNK were subsequently assayed by 
immunoprecipitation as described previously using the antibody of 
DNMT1, GST3β, or Mouse-IgG. The pull down protein complexes 
were then immunoblotted with antibodies of DNMT1, GST3β, or βTrCP 
to see whether there were interactions between these proteins. 
Ⅶ. DNMT1 protein phosphorylation induced by NNK 
-- Immunoprecipitation and Western blotting analysis 
Cells treated with 10 μM NNK  were assayed by 
immunoprecipitation using the antibody against DNMT1, phosphoserine 
proteins or Mouse-IgG. The pull down protein complexes were then 
immunoblotted with antibodies of DNMT1 or phosphoserine proteins to 
see whether there are phosphorylations of DNMT1 after NNK 
treatment. 
Ⅷ. DNMTs induced by NNK leading to hypermethylation on TSG 
promoters 
(a) Chromatin immunoprecipitation (ChIP)-PCR assay 
Cell-treated with NNK was
 cross-linked with 1% formaldehyde for 
15 min at 37°C and stopped by the addition
  of glycine to a final 
concentration of 0.125 M. Sonicate lysate on ice to shear DNA to   29
lengths between 200 and 800 bp. Subsequent steps were performed with 
the ChIP
 assay kit (Upstate Biotechnology, Lake Placid, NY) according
 
to the manufacturer’s instructions. Chromatin was immunoprecipitated 
for 16 h at 4°C using anti-DNMT1 (Imgenex), anti-DNMT3b (Asia 
Hepato Gene Co.). PCR analysis for anti-DNMT1 or anti-DNMT3b 
immuno-complex of the isolated DNA fragments used the
 following 
primer pairs: FHIT promoter, forward, 5'-   ATG CTT CTG CGC GTA 
TTG GC -3',
 and reverse, 5'-   GGT GAT GAC CTG ACG CG -3’; 
p16
INK4a promoter, forward, 5'- TTG AAG CTG GTC TTT GGAT -3, 
and reverse, 5'- ATC GAA ATC ACC TGT ACG ACT -3’; RARβ 
promoter, forward, 5'-  GGC AAC CAA CAT GGC TATTT -3',
 and 
reverse, 5'-  TAT AGT GGT CAA GAG CAT GGGT -3’; 
glyceraldehyde-3-phosphate dehydrogenase ( GAPDH) promoter as a 
negative control, forward, 5'-   AAT GAA AGG CAC ACT GTC TCT 
CTC -3',
 and reverse, 5'-   GTT TCT GCA CGG AAG GTC AC -3’. 
(b) Methylation specific-PCR (MSP) assay 
The promoter methylation status of the FHIT, p16
INK4a, and RARβ 
genes were determined by chemical treatment with sodium bisulfite, 
MSP analysis, and bisulfite-sequencing and their primer sequences are 
shown in Table 5. All PCRs were performed with positive controls for 
both unmethylated and methylated alleles and no DNA control. 
In animal model 
DNMT1, DNMT3b, p-AKT, p-GSK3β (ser9), and βTrCP protein 
expressions in mouse lung tissue   30
Normal lung and adenoma lung tissues from mice exposed to NNK 
were analyzed for  immunohistochemistry (IHC) assay to detect the 
expression levels of DNMT1 (60B1220, 1:30 dilution, Imgenex, San 
Diego, CA, USA) and DNMT3b (52A1018, 1:30 dilution, Genlantis, 
San Diego, CA, USA) proteins. In addition, the expression levels of 
p-AKT (736E11, 1:25 dilution, Cell signaling, Danvers, MA, USA), 
p-GSK3β (ser9) (1:25 dilution, abcam, US), and βTrCP (N-15, 1:300 
dilution, Santa Cruz Biotechonlogy, CA, USA) proteins were evaluated 
by IHC. These primary antibodies used and the reaction conditions in 
the present study are shown in  Table 2, then biotinylated secondary 
antibody for 40 min, streptavidin -horseradish peroxidase for 20 min 
(DAKO LSAB kit K0675, Dako, Glostrup, Denmark). 
3,3’-diaminobenzidine tetrahydrochloride was the chromagen. The 
evaluation of the IHC staining was conducted blindly. Staining was 
scored 3, 2, 1, or 0 for strong, medium, low, or negative nuclear stained 
for DNMT1 and DNMT3b, and cytoplasmic stained for p-AKT, 
p-GSK3β (ser9), and βTrCP. A score of 2 or 3 in more than 50% of 
stained area indicated the overexpression of DNMT1, DNMT3b, p-AKT, 
and p-GSK3β (ser9). A score of 1 or 0 in more than 50% of stained area 
indicated the presence of little or no βTrCP. 
In clinical model 
Tissue DNMT1 protein expression assay 
(a) Immunohistochemistry (IHC) assay 
The polyclonal antibody, anti-DNMT1 (A22659, aa 177-550; 1:200 
dilution; Asia Hepato Gene Co., Kaohsiung, Taiwan), was used as the   31
primary antibody to detect DNMT1 protein expression. The primary 
antibody was incubated for 4
oC overnight, then biotinylated secondary 
antibody for 30 min, streptavidin-horseradish peroxidase for 15 min 
(DAKO LSAB kit K0675, Dako, Glostrup, Denmark). 
3,3’-diaminobenzidine tetrahydrochloride was the chromagen. The 
evaluation of the IHC staining was conducted blindly, without 
knowledge of the clinical and pathologic characteristics of the cases. 
The surrounding non-neoplastic stroma served as an internal negative 
control for each slide. Staining was scored 3, 2, 1, or 0 for strong, 
medium, weak, and negative tumor nuclear stained respectively. 
DNMT1 overexpression was graded if more than 50% stained area 
showing 2 or 3. 
(b) Statistical analysis 
The SPSS program (SPSS Inc. Headquarters Chicago, Illinois) was 
used for all statistical analysis. The Pearson X
2 test was used to compare 
the frequency of DNMT1  alterations between NSCLC patients with 
different smoking status, and to study relationships between variables, 
such as DNMT1 protein expression levels in tumor samples.   32
RESULTS 
In cell model 
Ⅰ. Nicotine and NNK increase DNMTs expression 
The effect of cigarette-specific carcinogen exposure on DNMTs 
expression was examined in IMR90  normal lung cell and two lung 
carcinoma cell lines, A549 and H1299. The pro-carcinogen, 100 μM 
nicotine was added to culture medium of these cells at 0, 2, 4, 6, and 12 
h. At the end of treatment, treated and untreated cells were harvested 
then  proteins were isolated. Western blotting analysis revealed that 
exposure to nicotine induced a time-dependent increase in the level of 
DNMT1 and DNMT3b endogenous proteins  with most apparent 
induction at 6 hr in IMR90 (Fig. 4A), A549 (Fig. 4B), and H1299 cells 
(Fig. 4C). Similar experiment was also performed by using the 
carcinogen, NNK treatment. These cells were treated with 0, 0.01, 0.1, 
and 10 μM of NNK for 2 h.  Results indicated that NNK potently 
induced endogenous DNMT1 protein overexpression in a 
dose-dependent manner (Fig. 5A). In addition, these cells were treated 
with 10 μM NNK for 0, 30 min, 2 h, and 4 h. The results indicated that 
10 μM NNK promoted a time-dependent increase in the endogenous 
DNMT1 protein expression in three lung cells (Fig. 5B). We further 
examined whether NNK could induce exogenous DNMT1 expression 
by transfecting cells with  His-tagged full-length DNMT1 cDNA 
expression vector. The data showed that exogenous DNMT1 protein 
was also induced by NNK treatment (Fig. 5C). Finally, we analyzed   33
whether the DNMT1 induction by NNK occurred at the RNA level by 
RT-PCR assay of DNMT1 mRNA in  NNK-treated A549 and H1299 
cells.  The data demonstrated that NNK did not affect the mRNA 
expression level of DNMT1  (Fig.  5D). These results indicated  that 
nicotine and NNK increased endogenous and exogenous DNMTs 
protein levels. Note that NNK exhibited a strong induction of DNMT1 
protein in short term but did not affect DNMT1 mRNA level. 
Ⅱ. NNK prolongs DNMT1 protein half-life 
The increase of protein level may result from prolonged protein 
stability. Therefore, we measured DNMT1 protein half-life by Western 
blotting following 10 μg/ml cycloheximide (CHX) treatment,  which 
inhibits de novo protein synthesis. p53 protein, which has a short protein 
half-life, was used as a positive control. IMR90 and A549 cells showed 
an apparent degradation of DNMT1 protein levels at 6 h (Fig. 6A). To 
measure the kinetic changes of DNMT1 protein half-life upon NNK 
treatment, IMR90, A549, and H1299 cells were treated only with CHX 
for 0 h, 6 h, or combined treatment with 10 μM NNK for 6 h, 12 h, 24 h, 
and 48 h. The results indicated that 10 μM NNK prolonged DNMT1 
protein half-life compared to that of untreated cells. For example, CHX 
treatment alone at 6 h, DNMT1 protein expression levels were 39%, 53 
%, and 59% compared to untreated control for IMR90, A549, and 
H1299, respectively. However, these values of DNMT1 protein 
expression level increased to 63%, 79 %, and 92% upon CHX and NNK 
combinational treatment (Fig. 6B).  The results  suggested that NNK 
prolonged DNMT1 protein half-life and stabilized DNMT1 protein.   34
Ⅲ. Alterations of AKT, NFκB, Erk1/2, and p38 signaling proteins 
after NNK treatment 
Previous studies have shown that NNK stimulate phosphorylaiton 
of ERK1/2, AKT, and NFκB pathways (Schuller and Cekanova, 2005; 
Carlisle et al., 2007; Cekanova et al., 2007). Therefore, we validated the 
alterations of these pathways upon NNK treatment in IMR90 and A549 
cells. Our results indicated that AKT pathway was notably stimulated by 
NNK between 15 and 120 min in IMR90 and A549 cells.  NNK 
increased phosphorylation of NFκB with a maximum induction 
observed between 60 and 120 min in IMR90 cells. However, there was 
no significant phosphorylation of ERK1/2, whereas p38 was decreased 
after NNK treatment (Fig. 7). 
Ⅳ. NNK promotes DNMT1 protein stability through AKT signaling 
(a) NNK induces DNMT1 protein level by AKT signaling 
Since AKT pathway was notably stimulated by NNK in all cell lines 
tested  (Fig. 7), it is possible that NNK-induced DNMT1 protein 
expression through AKT pathway. To test this hypothesis, we first 
measured DNMT1 protein levels during NNK treatment in the presence 
of the inhibitor for AKT, LY294002. A549 cells were incubated with 10 
μM NNK for 2 h with or without pretreatment of 20 μM LY294002 for 
30 min. Results  indicated that LY294002 potently blocked 
NNK-induced DNMT1 protein overexpression (Fig. 8A). We further 
verified the role of AKT in NNK-induced DNMT1 overexpression by 
employing an siRNA knockdown assay for AKT. A549 and H1299 cells   35
were transfected with AKT siRNA for 48 h and treated with 10 μM 
NNK for 2 h, followed by Western blotting analysis. Results showed 
that the AKT siRNA potently and specifically reduced NNK-induced 
DNMT1 protein expression whereas the control siRNA had no effect 
(Fig. 8B). These findings provided evidences that AKT signaling was 
involved in induction of DNMT1 protein level by NNK. 
(b) NNK prolongs DNMT1 protein stability by AKT signaling 
pathway which is associated with ubiquitin proteosome system 
Since NNK prolonged DNMT1 protein stability by AKT signaling 
pathway (Figs. 6 and 8), we sought to find out whether AKT stabilized 
NNK-induced DNMT1 was mediated by the ubiquitin–proteasome 
pathway. A549 cells were treated with 10 μM NNK for 2 h, and cell 
lysates were immunoprecipitated with anti-DNMT1 antibody then 
Western blotted  with anti-DNMT1 or  anti-ubiquitin antibody. The 
results showed that NNK treatment reduced ubiquitination of DNMT1 
(Fig. 9A). In addition, A549 cells were treated with 20 μM LY294002 
(an AKT inhibitor) for 2 h, cell lysates were immunoprecipitated with 
anti-DNMT1 antibody then Western blotted  with anti-DNMT1 or 
anti-ubiquitin antibody. The data showed that  LY294002 treatment 
increased ubiquitination of DNMT1 (Fig. 9B). These results indicated 
that NNK-induced DNMT1 protein stability was mediated by AKT 
signaling pathway and was associated with ubiquitination protein 
degradation system. Furthermore, we treated A549 and IMR90 cells 
with 20 μM LY294002 for 30 min, then 20 μM proteasome inhibitor 
MG132 for 10 h before 10 μM NNK treatment for 2 h. The reduction of   36
NNK-mediated DNMT stability  by  LY294002 was abolished by 
MG132 (lane 4 in Fig. 9C). These results suggested that NNK-induced 
DNMT1 protein stability was associated with inhibition of proteosome 
degradation system via AKT pathway. 
Ⅴ. AKT downstream signaling proteins GSK3β and βTrCP enhance 
DNMT1 protein degradation 
GSK3β is an ubiquitously expressed protein serine/threonine kinase, 
which phosphorylates and activates an E3-ubiqutin ligase βTrCP 
(Hughes et al., 1993). Therefore, we investigated  whether 
GSK3β/βTrCP pathway involved in NNK-induced DNMT1 protein 
stability. A549 and IMR90 cells were treated with 25 μM SB415286, a 
GSK3β inhibitor, for 24 h before 2 h of NNK treatment. The results 
showed that increase of phosphorylation of GSK3β at site of serine 9, 
which is  an inactive form of GSK3β, after SB415286 treatment. 
Inactivation of GSK3β led to high DNMT1 protein basal level (compare 
the DNMT1 level in lane 3 to lane 1 and lane 7 to lane 5 in Fig.10). 
Cotreatment of SB415286 and NNK synergistically induced DNMT 
protein level (lane 4 and 8 in Fig. 10). To further validate the activation 
of GSK3β promotion of DNMT1 protein degradation, 
pCMV-SPORT6-GSK3β constructs were transfected into A549 cells for 
1 μg and 3 μg for 24 h. Overexpression of GSK3β gradually promoted 
the DNMT1 protein degradation as the amount of construct increased 
accordingly (Fig. 11A). Since βTrCP E3-ubiquitin ligase was involved 
in GSK3β-mediated proteosome degradation, we transfected 2 μg and 6 
μg of pCMV-SPORT6-βTrCP constructs into A549 cells for 24 h.   37
Overexpression of βTrCP also promoted the DNMT1 protein 
degradation at the dose-dependent manner (Fig. 11B). These results 
suggested that DNMT1 protein degradation system was mediated by 
GSK3β/βTrCP pathway. Furthermore, we investigated  whether 
NNK-induced DNMT1 protein levels can be weakened by activation of 
GSK3β/βTrCP pathway. A549 cells were transfected with  1  μg 
pCMV-SPORT6-GSK3β construct for 24 h, then treated with or without 
10  μM NNK for 2 h. The results indicated that NNK treatment 
attenuated DNMT1 protein degradation during  overexpression of 
GSK3β (Fig. 11C). 
Ⅵ. DNMT1 interacts with GSK3β and βTrCP 
The results in Fig. 11 suggested that NNK-induced DNMT1 protein 
stability resulted from attenuating the GSK3β/βTrCP-mediated DNMT1 
protein degradation. We further evaluated whether DNMT1 protein can 
interact with GSK3β and βTrCP. A549 cells were immunoprecipitated 
using DNMT1, GSK3β, or βTrCP antibodies, and then Western blotted 
with DNMT1, GSK3β, or βTrCP protein. The data demonstrated that 
DNMT1 protein indeed interacted with GSK3β and βTrCP (lanes 2~4 in 
Fig. 12A). In addition, we transfected his tagged-DNMT1 full length 
cDNA construct into A549 cells for 24 h, then treated the transfected 
cells with or without NNK for 2 h. The cells were immunoprecipitated 
using His tag antibody to pull down the exogenous DNMT1 protein, and 
then Western blotted with His tag-DNMT1, anti-GSK3β or anti-βTrCP 
antibodies. The results showed that exogenous DNMT1 protein 
decreased its interaction capacity with GSK3β and βTrCP proteins after   38
NNK treatment (decrease βTrCP and GSK3β in lane 5 compared to lane 
2 in Fig. 12B). 
Ⅶ. Overexpressed DNMT1 and 3b proteins bind to TSG promoters 
and result in promoter hypermethylation 
We then further investigated whether this induction of DNMTs by 
NNK can concomitantly activate DNMT binding to TSG promoters and 
result in 5’CpG hypermethylation of the bound TSG promoters. The 
recruitment of DNMT1 and DNMT3b to FHIT,  p16
INK4a, and RARβ 
promoters was determined by ChIP-PCR analysis (Fig. 13A). Binding 
of DNMT1 and DNMT3b to the tested TSG promoters increased 
significantly after exposure to NNK in IMR90 lung cells. The levels of 
promoter methylation in the tested TSGs were measured by a 
methylation-specific PCR assay (Fig. 13B). We found that induction of 
DNMT protein expression by NNK increases methylation levels of 
FHIT, p16
INK4a, and RARβ promoters in IMR90 normal lung cells. 
In animal model 
Cell model showed that NNK-induced DNMT1 protein stability was 
positive regulation with p-AKT. In addition, NNK-induced DNMT1 
protein stability was resulted from attenuating the 
GSK3β/βTrCP-mediated DNMT1 protein degradation. Therefore, we 
used immunohistochemical assay to stain the normal lung tissue slides 
of NNK-untreated mice and adenoma lung tissue slides of NNK-treated 
mice for DNMT1, DNMT3b, p-AKT, p-GSK3β (inactive form of ser9 
site), and βTrCP protein expressions to support the cell model data.   39
Ⅰ. NNK induces DNMT1, DNMT3b, p-AKT, and inactive form of 
p-GSK3β (ser9) proteins expression level in mouse adenoma 
lung tissue 
The proteins expression level of DNMT1, DNMT3b, p-AKT, and 
inactive form of p-GSK3β at site of serine 9 were increased in lung 
adenoma tissue of NNK-treated mice (Figs. 14A, C, E, and G) 
compared to the normal tissue of NNK-untreated mice (Figs. 14B, D, F, 
and H). 
Ⅱ. NNK reduces βTrCP protein expression level in mouse adenoma 
lung tissue 
Our cell model indicated that βTrCP, the E3 ubiquitin ligase, 
promoted DNMT1 protein degradation. Accordingly, the results of 
immunohistochemical staining of tissues from NNK-induced lung 
adenoma and NNK-untreated lung tissue from mice showed that the 
lung adenoma tissue of NNK-treated mice (Fig. 14I) had low protein 
expression of βTrCP compared to the normal tissue of NNK-untreated 
mice (Fig. 14J). 
In clinical model 
-- The DNMT1 overexpression correlates with smoking status of 
lung cancer patients 
Our recently study indicates that abnormally increase expression of 
DNMT1 protein is associated with smokers (Lin et al., 2007). Therefore, 
we further indentified whether DNMT1 expression level correlated with 
different smoking status of lung cancer patients. Immunohistochemical 
staining for the DNMT1 protein expression was performed on 109   40
NSCLC tumor samples with smoking status data available. DNMT1 
protein was highly expressed and localized in nuclear in tumor tissue of 
continuously smoking patients compared to surrounding non-neoplastic 
stroma tissue (Fig. 15A), but the expression level was relatively low in 
tumor tissue of ex-smoker patients (Fig. 15B) and non-smoking patients 
(Fig. 15C). The DNMT1 protein expression level was significantly 
higher in smoking patients compared to non-smoking patients including 
ex-smokers and never smokers (P<0.001)  (Table 6).  The DNMT1 
protein of ex-smoke patients were expressed only in 31.1% of patients 
analyzed compared to that of 69.4% found in still-smoking patients 
(P=0.001) (Table 6). 
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DISCUSSION 
DNA methylation is frequently not restricted to a single CpG island 
but affects multiple independent loci, reflective of a widespread 
deregulation of DNA methylation pattern in different types of tumors 
(Momparler, 2003; Belinsky, 2004). During lung
  tumorigenesis, 
overexpression of the three functional
 DNMTs (DNMT1, DNMT3a, and 
DNMT3b), which catalyze 5’CpG methylation, may lead to TSGs 
promoters methylation and caused cancer formation. In addition, we 
recently show that alteration of DNMTs expression correlates with 
multiple TSG promoter hypermethylation especially in smoking lung 
cancer patients (Lin et al., 2007). Therefore, increased DNMTs may play 
an etiological role by which cigarette-specific carcinogen-induced 
tumorigenicity. However, the mechanism in which cigarette smoke 
affects DNMTs expression is not clear.   
Previously studies find that cigarette smoke extract (CSE) induces 
DNMT1 protein levels in A549 lung cancer cell (Liu et al., 2007), but 
the effect of CSE on DNMT3a and DNMT3b protein levels have not 
been determined. In addition, DNMT1 protein levels are elevated in 
breast cancer tissues and in MCF-7 breast cancer cells compared to 
normal human mammary epithelial cells without an increase in DNMT1 
mRNA (Agoston et al., 2005). Our studies showed that DNMT1 and 
DNMT3b expression were induced by nicotine and DNMT1 expression 
was induced by cigarette-specific carcinogen, NNK, in A549 and H1299 
lung cancer cells, and IMR90 normal lung cells (Fig. 4). In addition,   42
NNK exhibited a strong induction of endogenous and exogenous 
DNMT1 protein in short term but did not affect DNMT1 mRNA level in 
lung normal and cancer cells (Fig. 5). Increase of DNMT1 protein level 
without changing of mRNA level after NNK treatment suggests that 
NNK-induced DNMT1 protein level was regulated at the translation 
and/or post-translational level.   
Our results revealed that NNK activated phosphorylation of AKT 
and NFκB proteins (Fig.7), supporting the previous findings that, AKT 
and NFκB activation by NNK (West et al., 2003; Tsurutani et al., 2005; 
E et al., 2006; Carlisle et al., 2007). Both AKT inhibitor compound and 
AKT siRNA knockdown treatments provided further evidences that 
AKT signaling plays a predominant role in induction of DNMT1 protein 
level by NNK (Fig. 8). 
NNK prolonged DNMT1 protein half-life and induced DNMT1 
protein level by AKT pathway (Figs. 6 and 8). In addition, our results 
reveal that NNK-induced DNMT1 protein stability was associated with 
inhibition of proteosome degradation system via AKT pathway (Fig. 9). 
These data suggested that NNK-induced DNMT1 protein level was 
regulated at the post-translational level. DNMT1 protein accumulation 
has been shown to be dependent on the N-terminal 120 amino acids, 
which seemed to function as a destruction domain in cells causing 
ubiquitination and proteasome-mediated degradation (Agoston et al., 
2005). A recent study has also suggested that N-terminal mediated 
DNMT1 protein stability control  is through activation of PI3K/AKT 
pathway (Sun et al., 2007). Note that the N-terminal 120 amino acid   43
domain of DNMT1 is important for  ubiquitination and 
proteasome-mediated degradation. Whether this region can be 
ubiqutinated by βTrCP, a ubiquitin ligase, needs to be determined by 
ubiqutination assay and βTrCP-DNMT protein interaction studies using 
a DNMT N-terminal deletion construct. Our data also provided clear 
evidence that NNK-induced DNMT1 protein stability resulted from 
attenuating the GSK3β/βTrCP which mediated DNMT1 protein 
degradation system (Figs. 10 and 11). Note that our result is the first 
study to demonstrate that DNMT1 protein interacts with GSK3β and 
βTrCP proteins (Fig. 12A). Moreover, NNK attenuates the interaction of 
DNMT1 protein with GSK3β and βTrCP proteins  (Fig. 12B). These 
data indicated that NNK-induced DNMT1 protein stability was 
mediated by GSK3β/βTrCP pathway. GSK3β is a ubiquitously 
expressed protein serine/threonine kinase, emerging as a regulator of 
neuronal, endothelial, and fibroblast death (Pap and Cooper, 2002; 
Sanchez et al., 2003). There are regulatory phosphorylations of GSK3α 
(Ser-21) and GSK3β (Ser-9) which inhibit their kinase activities through 
PKB/AKT  (Frame and Cohen, 2001; Cohen and Goedert, 2004). 
Therefore, we speculated that inactivated GSK3β through AKT may 
abolish the degradation of DNMT1 by βTrCP E3-ubiquitin ligase, and 
this mechanism was activated by NNK stimulation.   
GSK3β is also known to phosphorylate several substrates to create 
a recognition motif for betaTrCP, a ubiquitin ligase, thus providing for 
degradation of substrate protein through the ubiquitin-proteasome 
pathway  (Taketo, 2004).  Interestingly, our study found that   44
phosphorylation of DNMT1 was increased after NNK treatment for 2 h 
by immunoprecipitation assay (Fig. 16). However, it is not clear what 
phosphorylation site and the function of phosphorylated DNMT1 
proteins, which were induced by NNK. In addition, whether DNMT1 is 
a phosphorylated substrate of GSK3β remains unclear. Previous study 
shows that the GSK3β mediates nuclear factor activated T cell c (NFATc) 
nuclear export through direct phosphorylation, pointing that at least a 
fraction of GSK3β must be in nuclear (Beals et al., 1997). Diehl et al. 
(1998) points that phosphorylation of cyclin D1 on Thr-286 by GSK3β 
may occur in the nucleus to accelerate cyclin D1 export and cytoplasmic 
proteolysis. In addition, phosphorylation of the DNMT1 by AKT 
promotes its nuclear localization signal (NLS), which induction or 
enhancement of tumor growth via alteration of the components involved 
in the epigenetic programming of a cell (Hodge et al., 2007). Previous 
research suggests that phosphorylation of DNMT1 at Ser515 could be 
an important regulator of DNMT1 activity during cell cycle. The 
phosphorylation of Ser515 interacts between the N-terminal domain of 
DNMT1 and its catalytic domain that is necessary for activity (Goyal et 
al., 2007). In addition, DNMT1 can be phosphorylated at Ser396 but the 
function is unknown  (Grohmann et al., 2005).  Therefore, we will 
investigate whether NNK-induced phosphorylation of DNMT1 at sites 
of Ser515 and Ser396 by site-direct mutagenesis assays. In addition, 
whether DNMT1 phosphorylation can be decreased by inhibition of 
AKT or GSK3β will be validated. Searching for the kinase target motif 
of AKT and GSK3β in DNMT1 protein will be also performed. These   45
studies will gain insights of what mechanisms mediated DNMT1 
accumulation by NNK induction. 
We also found that cigarette-specific carcinogen, NNK, induced 
DNMT1 and DNMT3b proteins which bound and led to promoter 
hypermethylation of FHIT, p16 and RARβ TSGs (Fig. 13). The data 
supported that multiple TSGs show hypermethylation in smoker lung 
cancer patients may be mediated by tobacco smoke induced DNMTs 
overexpression. Our animal study also showed that NNK-induced 
adenoma in mice expresses DNMT1, DNMT3b, p-AKT, and inactive 
form of p-GSK3β proteins more than does NNK-untreated normal lung 
tissue. Interestingly, the NNK-induced adenoma in mice shows less 
expression level of βTrCP than that of NNK-untreated normal lung 
tissue (Fig. 14). However, the expression level of these proteins is not 
specifically different in adenoma lung tissue from its surrounding 
normal lung tissue with NNK-treated mice. These data suggest that once 
NNK is there, it will affect all cells and some cells may be more 
susceptible than the others because of their genomic instability in nature 
so they became adenoma. However, if there is no NNK, all the proteins 
express normally, according to our NNK-untreated normal lung tissue 
from mice and the patients who quit smoking (Figs. 14 and 15). It 
suggests that effect of NNK is quick, transient, and reversible upon 
release of NNK treatment. 
In addition, our previously clinical data showed that smoker 
patients have higher level of DNMT1 protein expression than that of 
nonsmokers. When both DNMT1 and DNMT3b overexpressed, there is   46
a significant correlation between DNMTs overexpression and 
hypermethylation of multiple TSGs in smoking SQ patients (Lin et al., 
2007). Many clinical studies found that multiple hypermethylation of 
TSG promoters are associated with smoking (Kim et al., 2001; 
Zochbauer-Muller et al., 2001). These results imply that the association 
between DNMT overexpression, TSG promoter hypermethylation, and 
smoking may be clinically relevant. Interestingly, our recently data 
found that DNMT1 expression level decreases as patients quit smoking, 
suggesting that the effects of cigarette carcinogen on DNMT1 
expression may be transient and can be reversible by quitting smoking 
(Fig. 15 and Table. 6). 
In summary, our studies suggested that cigarette-specific 
carcinogen, NNK induces DNMT1 protein level by AKT signaling 
pathway. NNK induced activation of AKT then promotes GSK3β 
phosphorylation at serine 9 to form an inactive-GSK3β, which results in 
attenuating E3 ubiquitination ligase,  βTrCP  for its ability  to degrade 
DNMT1 protein. Note that we identified for the first time that DNMT1 
protein indeed interacts with GSK3β and βTrCP proteins. These data 
provide evidences that AKT/GSK3β/βTrCP signaling pathway involves 
in NNK-induced DNMT1 protein stability. Furthermore, these 
NNK-induced DNMT1 proteins bind to promoter of various tumor 
suppressor genes  and result in promoter hypermethylation, which 
ultimately leads to tumorigenesis (Fig. 17).    47
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Table 1. The studies of DNMTs expression in human cancers. 
1 N: number of patients showing alteration. 
2 RT-PCR: reverse-transcriptase polymerase chain reaction 
IHC: immunohistochemistry 
 
DNMTs   Tumor  types Alterations  N
1 (%)  Detection
2  Ref. 
DNMT1 Colorectal 
cancer 
Overexpression  IHC  (De Marzo et al., 
1999) 
DNMT1 
DNMT3a 
DNMT3b 
Hepatocellular 
carcinoma 
Overexpression 42 (63%) 
48 (72%) 
45 (67%) 
RT-PCR  (Saito et al., 2001) 
DNMT1  prostate cancer Overexpression 20 (100%) IHC  (Patra et al., 2002) 
DNMT1 Hepatocellular 
carcinoma 
Overexpression 23 (43%)  IHC  (Saito et al., 2003) 
DNMT1 
 
Transitional 
cell carcinoma 
Overexpression 151 (87%) IHC  (Nakagawa et al., 
2003) 
DNMT1 
DNMT3a 
DNMT3b 
Breast cancer Overexpression 7  (5.4%) 
4 (3.1%) 
39 (30%) 
Real-time 
RT-PCR 
(Girault et al., 2003)
DNMT1 gastric cancer Overexpression 92 (72%)  IHC  (Etoh et al., 2004) 
DNMT1 
DNMT3b 
Lung cancer  Overexpression 14 (24%) 
25 (44%) 
IHC  (Lin et al., 2005) 
 
DNMT1 
DNMT3b 
Lung cancer  Overexpression 54 (53%) 
59 (58%) 
RT-PCR  (Kim et al., 2006) 
DNMT1 
DNMT3a 
DNMT3b 
Lung cancer  Overexpression 46 (46%) 
30 (30%) 
31 (31%) 
RT-PCR  (Lin et al., 2007) 
DNMT1 
DNMT3a 
DNMT3b 
Lung cancer  Overexpression 45 (45%) 
23 (32%) 
31 (31%) 
IHC  (Lin et al., 2007) 
DNMT3a 
DNMT3b 
Liver cancer  Overexpression 21 (75%) 
16 (60%) 
Real-time 
RT-PCR 
(Xiao et al., 2008)   58
Table 2. The antibodies and their reaction conditions used in the present study. 
Target K.D. Raised 
In  Application Dilution Source  Catalog 
No. 
Western blot  1:10000
Immunoprecipitation 1:100 Chicken 
Immunohistochemistry 1:250
Asia Hepato 
Gene Co.  A22659
Anti-DNMT1 190 
Mouse  Immunohistochemistry 1:30 Imgenex  IMG261A
Rabbit  Western blot  1:000 Cell Signaling  2161S 
Anti-DNMT3b 110 
Mouse  Immunohistochemistry 1:30 Genlantis  ABI184
Anti-β-actin 42  Mouse  Western blot  1:5000 Novus 
Biologicals 
NB 
600-501
Anti-p53 
Clone:DO-7  53 Mouse  Western blot  1:1000 DAKO M  7001
Anti-AKT 60  Rabbit  Western blot  1:1000 Cell Signaling  9272 
Western blot  1:500 9271  Anti-phospho- 
AKT (Ser473)  60 Rabbit 
Immunohistochemistry 1:30 
Cell Signaling 
3787 
Anti-Erk1/2 42,44 Rabbit  Western blot  1:1000 Upstate 06-182 
Anti-phoph- 
Erk1/2  42,44 Mouse  Western blot  1:1000 Upstate 05-481 
Anti-phosph- 
p38 (Thr180)  38 Rabbit  Western blot  1:1000 Chemicon AB3828
Anti- NFκB 65  Rabbit  Western blot  1:1000 Upstate 06-418 
Anti-phopho- 
NFκB (Ser536)  65 Rabbit  Western blot  1:1000 Cell Signaling  3031 
Western blot  1:5000
Anti-GSK3β  46 Rabbit 
Immunoprecipitation 1:125
Cell Signaling  9315 
Western blot  1:500 Anti-phosph- 
GSK3β (Ser9) 
46 Rabbit 
Immunohistochemistry 1:25 
Abcam Ab9769
Mouse  Western blot  1:500 Zymed 37-3400
Anti-βTrCP  70 
Goat  Immunohistochemistry 1:300 Santa Cruz  SC-8862
Western blotting  1:500
Anti-ubiquitin -- Mouse 
Immunoprecipitation 1:50 
Chemicon MAB1510
Anti-His tag  --  Rabbit  Western blotting  1:500 Cell Signaling  2365 
-- Molecular weight is variable.   59
Table 3. The cell lines and their characteristics used in the current study. 
Cell Name  Medium
1  Characteristics 
IMR90 DMEM
  Normal Fibroblast lung cell 
A549 DMEM  adenocarcinoma 
H1299  DMEM  Large cell lung carcinoma 
1 DMEM (Dulbecco
’s Modified Eagle
’s Medium) 
RPMI (Rosewell Park Memorial Institute) 
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Table 4. The plasmids and their characteristics used in the current study. 
Plasmid Target 
Insert 
(bp) 
Function Source 
pcDNA3-V5-TOPO-
His vector 
Non  0  Vector control  From Dr. L-J Juan 
pcDNA3-V5-TOPO-
His-full length 
cDNA DNMT1 
Wild type DNMT1 4850 Overexpression From Dr. L-J Juan
pCMV-SPORT6- 
vector 
Non 0  Vector  control  Homemade 
pCMV-SPORT6- 
GSK3β 
Wild type GSK3β 1301 Overexpression Homemade 
pCMV-SPORT6- 
βTrCP 
Wild type βTrCP 1817 Overexpression Open  Biosystems   61
Table 5. List of primer sequences and their reaction conditions used in the present study. 
Gene primer  5’Æ 3’ sequences  PCR size (bp) Tm  Cycle number 
Forward ACCGCTTCTACTTCCTCGAGGCCTA DNMT1 
Reverse GTTGCAGTCCTCTGTGAACACTGTGG
334 60
oC 30 
β-actin  Forward 
Reverse 
ACACTGTGCCCATCTACGAGG 
AGGGGCCGGACTCGTCATACT  618  60
oC 30 
Forward GTTTTTTTGTTTGGAAAGATAT  p16-methyl-MSP-O 
Reverse CTACCCATCATCATAACCTAAATC
232 54
oC 35 
Forward TTATTAGAGGGTGGGGTGGATTGT p16-methyl-MSP-U 
Reverse CAACCCCAAACCACAACCATAA 
151 65
oC 35 
Forward TTATTAGAGGGTGGGGCGGATCGC p16-methyl-MSP-M 
Reverse GACCCCCGAACCGCGACCTAA 
150 65
oC 35 
Forward AAGTGAGTTGTTTAGAGGTAGGAGGG RARβ-methyl-MSP-O 
Reverse CCTATAATTAATCCAAATAATCATTTACC
280 54
oC 35 
Forward TTGAGAATGTGAGTGATTTGA  RARβ-methyl-MSP-U 
Reverse AACCAATCCAACCAAAACAA 
146 54
oC 35 
Forward TCGAGAACGCGAGCGATTCG  RARβ-methyl-MSP-M 
Reverse GACCAATCCAACCGAAACGA 
146 54
oC 35 
Forward TAGTGGGTATATTTTTAG  FHIT-methyl-MSP-O 
Reverse ATCCCACCCTAAAACCTC 
249 50
oC 40 
Forward GAAGGTAGGGGTGGGGAGGTAAGTT FHIT-methyl-MSP-U 
Reverse CATAAACAACACCAACCCCACTA
116 68
oC 35 
Forward GAAGGTAGGGGCGGGGAGGTAAGTT FHIT-methyl-MSP-M 
Reverse CGTAAACGACGCCGACCCCACTA
116 68
oC 35   62
Forward TTGAAGCTGGTCTTTGGAT  p16-promoter 
Reverse ATCGAAATCACCTGTACGACT 
400 65
oC 35 
Forward GGCAACCAACATGGCTATTT  RARβ-promoter 
Reverse TATAGTGGTCAAGAGCATGGGT 
401 65
oC 35 
Forward ATGCTTCTGCGCGTATTGGC  FHIT-promoter 
Reverse GGTGATGACCTGACGCG 
323 61
oC 35 
Forward AATGAAAGGCACACTGTCTCTCTC GAPDH-promoter 
Reverse GTTTCTGCACGGAAGGTCAC 
218 65
oC 35   63
Table 6.  Overexpression of DNMT1 protein in relation to the 
smoking patients of resected NSCLC tumors.
1 
       D N M T 1   p r o t e i n       
Total Non-overexpression Overexpression  Characteristics 
N  N (%)  N (%) 
Overall  109  61 (56.0)  48 (44.0) 
 
Smoking
2          
habit  smoker  36  11 (30.6)  25 (69.4) 
  Non-smoker  73  50 (68.5)  23 (31.5)
<0.001 
         
  Still-smoker  36  11 (30.6)  25 (69.4) 
  Ex-smoker  45  31 (68.9)  14 (31.1)
0.001 
 Never  smoker  28  19  (67.9) 9  (32.1) 
1. These results were analyzed by the Fisher's Exact Test. P values 
with significance are shown as superscripts. 
2 The Non-smoker group includes ex-smoker and never smoker.   64
 
 
 
Figure 1. Structures of benzo[a]pyrene and tobacco-specific nitrosamines. 
In relation to human lung cancer, the most important carcinogens are PAHs such as 
benzo[a]pyrene and the tobacco specific nitrosamine family.  (A) The major 
metabolic pathway of benzo(a)pyrene leading to the ultimate carcinogen, 
benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE). (B) With the exception of 
4-(methyl-nitrosamino)-4-(3-pyridyl)-butanal NNA, all nitrosamines have been 
detected in tobacco products. In addition, NNK is considered to be a major 
contributor to lung carcinogenesis in smokers. CYP, cytochrome P450. [Figure and 
legends were modified from (Hecht, 1999, 2002)].   65
 
 
Figure 2. Schematic of NNK metabolism. 
Nicotine in cigarette smoke can be converted into carcinogen such as NNK which is 
metabolically activated by cytochrome P450. Some of the intermediates formed by 
the interaction of cytochrome P450 enzyme with carcinogens are reactive to DNA to 
form DNA damage. These intermediates have electrophilic affinity center then lead 
to react with DNA, and result in the formation of covalently bound products known 
as DNA adducts. The major metabolic event of NNK is conversion of the carbonyl 
group in NNK to an alcohol with the formation of NNAL. This product is also a 
potent pulmonary carcinogen. NNAL in turn is metabolized by glucuronidation of 
the alcohol and pyridine ring (NNAL-N-Gluc and NNAL-O-Gluc; collectively 
NNAL glucuronide, NNAL-Gluc). NNAL is conjugated to its presumed detoxified 
product, NNAL-Gluc, by UDP-glucuronosyltransferases (UGTs) and then is 
excreted in the urine. [Figure and legends were modified from (Muscat et al., 
2005)].   66
 
 
Figure 3. Functional domain of human methyltransferase family members. 
In the N-terminal part the sub-domain organization is shown: PCNA binding site 
(PBD), nuclear localization signal region (NLS), replication foci targeting domain 
(RFTD), cysteine rich region (CR) and bromo-adjacent homology domains (BAH). 
Additionally PWWP domain (involved in protein–protein interactions) and the 
ATRX domain (involved in histone deacetylase interactions) are also shown. In the 
C-terminal part the highly conserved motifs are shown as black thick lines. 
C-terminal domain contains the catalytic function of DNA methyl transfer. [Figure 
and legends were modified from (Siedlecki and Zielenkiewicz, 2006)].   67
 
 
Figure 4. Nicotine induces DNMTs protein levels time-dependently. 
Normal lung cell line, IMR90 was treated with 100 μM nicotine for various times as 
indicated (A). Lung cancer cell lines, A549 and H1299 were treated with 100 μM 
nicotine for various times as indicated (B and C). Cells were harvested, washed, and 
lysed in detergent buffer. Expression levels of endogenous DNMT1 or DNMT3b in 
various human lung cell lines were analyzed by Western blotting using DNMT1 or 
DNMT3b antibody, respectively. β-actin antibody was used to confirm the protein 
quality and to quantify the protein level.   68
 
 
Figure 5. NNK increases endogenous and exogenous DNMTs protein levels in 
dose-dependent and time-course manners. 
(A) IMR90, A549, and H1299 lung cell lines were treated with various 
concentrations of NNK for 2 h. (B) IMR90, A549, and H1299 lung cell lines were 
treated with 10 μM NNK for various times as indicated. (C) His-tagged DNMT1 
full-length cDNA constructs were transfected into A549 and H1299 cell lines for 24 
h, then treated with 10 μM NNK for 2 h. Expression levels of endogenous and 
exogenous DNMT1 in various human lung cell lines were analyzed by Western 
blotting using DNMT1 or His-tag antibody, respectively. β-actin antibody was used 
as an internal control. (D)  NNK-treated A549 and H1299 cells for 2 h did not 
change the  endogenous  DNMTs mRNA expression levels measured by RT-PCR. 
Expression of the housekeeping gene β-actin was used as an internal control for 
RNA integrity.   69
 
 
Figure 6. NNK prolongs DNMT1 protein half-life. 
(A) IMR90 and A549 cell lines were treated with 10 μg/ml cycloheximide (CHX) 
for the time periods as indicated. (B) IMR90, A549, and H1299 cell lines were 
treated with 10 μg/ml CHX with or without 10 μM NNK for longer time to measure 
the kinetic changes of protein half-life of DNMT1 after NNK treatment. DNMT1 
protein levels were determined by Western blotting (upper panel) and densitometry 
(lower panel). White bars: cells treated with DMSO as an experiment control. Gray 
bars: cells treated with CHX for 6 h. Dot bars: cell treated with CHX and NNK for 
various times as indicated. Experiments were performed three times and standard 
deviation was shown. P values are as indicated. β-actin is a loading control and p53 
serves as a positive control for CHX treatment since its half-life is known to be 
short.   70
 
 
Figure 7. The signaling pathways induced by NNK. 
IMR90 normal lung cell line and A549 lung cancer cell lines were treated with 10 
μM NNK for various times as indicated (A). Phosphorylation of AKT was analyzed 
by Western blotting using phospho-specific AKT Ser473 antibody. Total AKT 
antibody was used to confirm and quantify AKT protein. Western blot analysis was 
performed to detect phosphorylated NFκB or total NFκB by using a 
phospho-specific NFκB or total NFκB antibodies; phosphorylated ERK1/2 or total 
ERK1/2 by using a phospho-specific ERK1/2 or a mixture of ERK1 and ERK2 
antibodies. Phosphorylation of p38 was analyzed by Western blotting using 
phosphor-p38 antibody. β-actin is an internal control. Quantitative figures are 
determined from three experiments and P values are as indicated (B). 
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Figure 8. NNK induces DNMT1 protein level by AKT pathway. 
(A)  A549 cell line was pretreated with or without 20 μM LY294002, an AKT 
inhibitor, for 30 min then treated with 10 μM NNK for 2 h. The activation of AKT 
by NNK was measured by Western blot (upper panel) and densitometry (lower 
panel). (B) A549 and H1299 cell lines were transfected with AKT siRNA or control 
siRNA, as described in “Materials and Methods” Briefly, cells were pretreated in the 
absence or presence of si-AKT for 48 h then treated with 10 μM NNK for 2 h. 
Following, cells were harvested, washed, and lysed in detergent buffer. Protein 
expression level of DNMT1, phosphorylation of AKT, and total AKT were analyzed 
by Western blotting with β-actin as internal control (upper panel) and densitometry 
(lower panel). P values are as indicated.   72
 
 
Figure 9. NNK enhances DNMT1 protein stability by AKT signaling pathway 
which is associated with ubiquitin proteosome system. 
A549 cells were treated with 10 μM NNK for 2 h (A) or treated with 20 μM 
LY294002 for 2 h (B). Cell lysates were immunoprecipitated with anti-DNMT1 
antibody and Western blotted with anti-DNMT1 or anti-ubiquitin antibodies. 
Anti-IgG is a negative control. (C) A549 cells were treated with 10 μM NNK for 2 h 
with or without pretreated with 20 μM LY294002 for 30 min. In addition, cells were 
pretreated with 20 μM LY294002 for 30 min, then with 20 μM MG132 for 10 h, 
followed by treated with 10 μM NNK for 2 h. Protein expression level of DNMT1 
and phosphorylation of AKT were analyzed by Western blotting with β-actin as an 
internal control (left panel). Densitometry showing the change of DNMT1 protein 
level was determined by three experiments (right panel). P values are as indicated.   73
 
 
Figure 10. GSK3β involves in DNMT1 protein degradation and the increase of 
DNMT1 protein level by NNK. 
A549 and IMR90 cells were treated in the absence or presence of 25 μM GSK3β 
inhibitor, SB415286 for 24 h, and then treated with 10 μM NNK for 2 h. Increasing 
of DNMT1 protein expression after inhibition of GSK3β activity was observed. 
Phosphorylation of GSK3β-ser9 is an inactive form of GSK3β. Protein expression 
levels of DNMT1, phosphorylation of GSK3β-ser9, and total GSK3β were analyzed 
by Western blotting with β-actin as an internal control (upper panel). Densitometry 
showing the change of DNMT1 protein level, which was determined by three 
experiments (lower panel). P values are as indicated.   74
 
 
 
Figure 11.  GSK3β/βTrCP pathway promotes DNMT1 protein degradation 
which is attenuated by NNK treatment. 
pCMV-SPORT6-GSK3β  (A) or pCMV-SPORT6-βTrCP  (B)  constructs were 
transfected into A549 cells for various doses as indicated. After over-expressing of 
GSK3β or βTrCP, the DNMT1 proteins were degraded as the amount of construct 
increased accordingly. (C) A549 cells were transfected with 1 μg 
pCMV-SPORT6-GSK3β for 24 h, then treated with or without 10 μM NNK for 2 h. 
NNK treatment attenuated DNMT1 protein degradation along with decrease of total   75
GSK3β and increase of βTrCP (lane 3). Protein expression levels of DNMT1, total 
GSK3β, and βTrCP were analyzed by Western blotting with β-actin as an internal 
control (left panel). Densitometry showing the change of DNMT1 protein level, 
which was determined by three experiments (right panel). P values are as indicated.   76
 
 
Figure 12. DNMT1 protein interacts with GSK3β and βTrCP proteins. 
(A)  A549 cells were harvested, washed, and lysed in detergent buffer. 
Immunoprecipitation experiment was performed using DNMT1, GSK3β, or βTrCP 
antibodies. Precipitated proteins then Western blotted with anti-DNMT1, 
anti-GSK3β, or anti-βTrCP antibodies, respectively. (B)  His-tagged DNMT1 
full-length cDNA constructs were transfected into A549 cells for 24h, then treated 
with or without 10 μM NNK for 2 h. Cell lysates were immunoprecipitated with His 
tag antibody and Western blotted with anti-His tag DNMT1, anti-GSK3β, or 
anti-βTrCP antibodies. Anti-IgG is a negative control.   
   77
 
 
Figure 13.  Binding of DNMT1 and DNMT3b proteins to their target TSG 
promoters is induced by NNK. 
(A) ChIP-PCR using DNMT1 and DNMT3b antibodies for amplification of FHIT, 
p16
INK4a, and RARβ promoters before and after NNK treatments for 48 h in IMR90 
cells. (B) MSP for promoter hypermethylation status in the FHIT, p16
INK4a, and 
RARβ promoters before and after NNK treatments for 3 days in IMR90 cells.   78
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Figure 14. Representative figures of immunohistochemistry analysis of DNMT1, 
DNM3b, p-AKT, p-GSK3β(ser9), and βTrCP in paraffin sections of lung 
adenoma of NNK-untreated mice and treated mice. 
The immunohistochemical stained with normal lung tissue of NNK-untreated mice 
and lung adenoma tissue of NNK-treated mice for DNMT1 (A and B), DNMT3b (C 
and D), p-AKT (E and F), p-GSK3β (inactive form of ser9 site) (G and H), and 
βTrCP protein expression (I and J). The proteins expression level of DNMT1, 
DNMT3b, p-AKT, and inactive form of p-GSK3β at site of serine 9 were increased 
in lung adenoma tissue of NNK-treated mice compared to the normal lung tissue of 
NNK-untreated mice. In addition, the lung adenoma tissue of NNK-treated mice had 
low protein expression of βTrCP compared to the normal lung tissue of 
NNK-untreated mice. (Original magnification ×400).   80
 
 
Figure 15. Representative figures of immunohistochemistry analysis of DNMT1 
in paraffin sections from lung cancer patients of smoker, ex-smoker, or never 
smoker. 
The immunohistochemical stainings for DNMT1 protein expression of resected 
tumor specimens from a smoking patient (A), an ex-smoker patient (B), and a never 
smoker patient (C) are shown. DNMT1 nuclear positive immunoreactivity was 
found in smoking patient. Decreasing of DNMT1 nuclear immunoreactivity was 
found in ex-smoker and never smoker patients. (Original magnification ×200). 
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Figure 16. NNK increases phosphorylation of DNMT1 protein in A549 cells. 
A549 cells were treated with or without 10μM NNK for 2 h, and then cell lysates 
were immunoprecipitated with anti-DNMT1 or anti-phosphoserine antibodies. IgG 
antibody is a negative control. Precipitated proteins  then Western blotted with 
anti-DNMT1 or anti-phosphoserine antibodies, respectively. Phosphserine-DNMT1 
protein expression was increased after NNK treatment. 
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Figure 17. Proposed model of NNK promoted DNMT1 protein stability by 
AKT/GSK3β/βTrCP signaling pathway. 
NNK induces activation of AKT then promotes GSK3β phosphorylation at serine 9 
to form an inactive-GSK3β, which results in attenuating E3 ubiquitination ligase, 
βTrCP  for its ability  to degrade DNMT1 protein. AKT/GSK3β/βTrCP signaling 
pathway involves in NNK-induced DNMT1 protein stability. Furthermore, these 
NNK-induced DNMT1 proteins bind to promoter of various tumor suppressor genes 
and result in promoter hypermethylation, which ultimately leads to tumorigenesis. 
 